Physician profile
Javier Perez
NPI 1609855089
$5,014.81
in general payments reported to CMS, 2019-2025
22 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $299 · 2021: $755 · 2022: $429 · 2023: $643 · 2024: $558 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,287.49 | 2019-2025 | Clareon, Clareon Panoptix Pro, Unity |
| Johnson & Johnson Surgical Vision, INC. | $1,072.93 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| New World Medical,INC. | $602.50 | 2019-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Sight Sciences, INC. | $365.93 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $312.87 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Ocular Therapeutix, INC. | $248.57 | 2021-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $202.85 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $149.91 | 2019-2023 | Cequa |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Eylea Hd |
| Allergan, INC. | $120.56 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $118.14 | 2019-2021 | |
| Abbvie INC. | $110.13 | 2022-2024 | |
| Rayner Intraocular Lenses Limited | $60.44 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Novartis Pharmaceuticals Corporation | $46.73 | 2021-2022 | |
| Harrow Eye, LLC | $46.69 | 2024-2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $36.59 | 2024 | Xdemvy |
| Amgen INC. | $21.26 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.22 | 2021 | |
| Biotissue Holdings INC. | $17.70 | 2021 | |
| Glaukos Corporation | $17.37 | 2024 | Radius |
| Rxsight INC | $16.60 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Dompe US, INC. | $16.33 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.